ES2526648T3 - Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno - Google Patents

Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno Download PDF

Info

Publication number
ES2526648T3
ES2526648T3 ES08799127.9T ES08799127T ES2526648T3 ES 2526648 T3 ES2526648 T3 ES 2526648T3 ES 08799127 T ES08799127 T ES 08799127T ES 2526648 T3 ES2526648 T3 ES 2526648T3
Authority
ES
Spain
Prior art keywords
oxidative stress
working memory
improve oxidative
subject
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08799127.9T
Other languages
English (en)
Inventor
James A. Joseph
Agnes M. Rimando
Barbara Shukitt-Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Agriculture USDA
Original Assignee
US Department of Agriculture USDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Agriculture USDA filed Critical US Department of Agriculture USDA
Application granted granted Critical
Publication of ES2526648T3 publication Critical patent/ES2526648T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composición farmacéutica que contiene una cantidad terapéutica efectiva de pteroestilbeno sustancialmente puro de fórmula:**Fórmula** y un vehículo fisiológicamente aceptable, para emplearla en el tratamiento de déficits motores y/o enfermedades neurodegenerativas, incrementando la actividad receptora de acetilcolina en el sujeto mediante la administración de una cantidad de pteroestilbeno comprendida aproximadamente entre 2,5 mg y 10 mg por kilogramo de peso corporal del sujeto.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES08799127.9T 2007-09-07 2008-09-04 Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno Active ES2526648T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97059107P 2007-09-07 2007-09-07
US970591P 2007-09-07
US136341 2008-06-10
US12/136,341 US20090069444A1 (en) 2007-09-07 2008-06-10 Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
PCT/US2008/075170 WO2009032870A2 (en) 2007-09-07 2008-09-04 Method to ameliorate oxidative stress and improve working memory via pterostilbene administration

Publications (1)

Publication Number Publication Date
ES2526648T3 true ES2526648T3 (es) 2015-01-14

Family

ID=40429677

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08799127.9T Active ES2526648T3 (es) 2007-09-07 2008-09-04 Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno

Country Status (11)

Country Link
US (3) US20090069444A1 (es)
EP (1) EP2200597B1 (es)
JP (1) JP5608082B2 (es)
KR (1) KR20100075468A (es)
CN (2) CN103083288B (es)
AU (1) AU2008296293A1 (es)
BR (1) BRPI0816317A2 (es)
CA (1) CA2698661C (es)
ES (1) ES2526648T3 (es)
HK (2) HK1148932A1 (es)
WO (1) WO2009032870A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
EP2445488B1 (en) * 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
US20100119499A1 (en) * 2009-09-17 2010-05-13 Kneller Bruce W Stilbene-based compositions and methods of use therefor
US20110280850A1 (en) * 2010-05-12 2011-11-17 Starr Elizabeth I Compositions Containing DNA Repair Enzyme And Anogeissus Extract
US20120237494A1 (en) * 2010-09-30 2012-09-20 Daly Susan M Compositions Containing Zinc PCA And Anogeissus Extract
EP2537513A3 (en) * 2011-03-11 2015-04-29 ELC Management LLC Use of anogeissus extract for fibrillin production in skin
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
US20130072509A1 (en) * 2011-09-15 2013-03-21 ChromaDex Inc. Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation
JP6155191B2 (ja) * 2011-10-02 2017-06-28 キユーピー株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途
JP5901547B2 (ja) 2012-03-28 2016-04-13 富士フイルム株式会社 組成物、これを含む皮膚外用剤、又は機能性食品
EP3063163B1 (en) 2013-10-30 2022-08-10 Chromadex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2017011318A1 (en) 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
CA3034673A1 (en) 2016-08-22 2018-03-01 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
US9975915B1 (en) 2016-11-11 2018-05-22 The Queen's University Of Belfast Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用
KR20200144125A (ko) 2018-05-15 2020-12-28 알카헤스트 인코포레이티드 류코트리엔 a4 가수분해효소의 조정제를 이용한 노화-연관 질환의 치료
JP7345312B2 (ja) * 2019-08-09 2023-09-15 キユーピー株式会社 発酵乳
CN112618520A (zh) * 2021-01-14 2021-04-09 姚大纯 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038125A1 (en) * 2003-08-15 2005-02-17 Smit Hobbe Friso Method for the treatment of arthritis and pain
JP4633572B2 (ja) * 2004-07-30 2011-02-16 イスクラ産業株式会社 糖尿病改善剤
US20060057231A1 (en) * 2004-08-19 2006-03-16 Rimando Agnes M Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration

Also Published As

Publication number Publication date
CN101820869A (zh) 2010-09-01
JP5608082B2 (ja) 2014-10-15
CN103083288A (zh) 2013-05-08
HK1185257A1 (zh) 2014-02-14
CA2698661C (en) 2016-03-29
US20090069444A1 (en) 2009-03-12
CA2698661A1 (en) 2009-03-12
EP2200597B1 (en) 2014-11-12
HK1148932A1 (en) 2011-09-23
CN101820869B (zh) 2012-12-12
KR20100075468A (ko) 2010-07-02
WO2009032870A3 (en) 2009-05-22
EP2200597A4 (en) 2010-09-08
AU2008296293A1 (en) 2009-03-12
US20120035272A1 (en) 2012-02-09
EP2200597A2 (en) 2010-06-30
US9028887B2 (en) 2015-05-12
WO2009032870A2 (en) 2009-03-12
JP2010538077A (ja) 2010-12-09
US8809400B2 (en) 2014-08-19
US20140256827A1 (en) 2014-09-11
CN103083288B (zh) 2016-04-13
BRPI0816317A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
RU2013111077A (ru) Дипептидное пролекарство, его применение и лекарственное средство
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
PE20040121A1 (es) Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno
PE20120654A1 (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
AR087744A1 (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
JP2012508256A5 (es)
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
AR036312A1 (es) Composicion farmaceutica
ECSP077843A (es) Tratamiento o prevención del prurito
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre